Stay updated on Guselkumab vs Ustekinumab in Psoriasis Clinical Trial

Sign up to get notified when there's something new on the Guselkumab vs Ustekinumab in Psoriasis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Guselkumab vs Ustekinumab in Psoriasis Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a shift in the number of weeks for the study duration from 60 to approximately 64 weeks. This change may impact the safety evaluations and monitoring period for participants in the clinical trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:50:20.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying the health conditions and prior treatments required for inclusion in the study on plaque-type psoriasis. Previously, no information was provided under the participation criteria section.
    Difference
    19%
    Check dated 2024-05-22T21:38:13.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:40:43.000Z thumbnail image

Stay in the know with updates to Guselkumab vs Ustekinumab in Psoriasis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Guselkumab vs Ustekinumab in Psoriasis Clinical Trial page.